LFSC — F/m Emerald Life Sciences Innovation ETF
Data updated: 2026-07-28
LFSC — F/m Emerald Life Sciences Innovation ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $105.06M AUM · 0.54% expense ratio · 72.1% 1-yr return. From SEC regulatory filings.
LFSC Fund Overview
LFSC — F/m Emerald Life Sciences Innovation ETF is a US mutual fund managed by Rbb Fund, Inc., categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Rbb Fund, Inc.
- Category: United States Health Care Equity
- Assets under management: $105.06M
- 1-year return: 72.1%
- Ticker: LFSC
- SEC CIK: 0000831114
- SEC series ID: S000088167
- Share class ID: C000254221
LFSC Holdings
Top 10 holdings of F/m Emerald Life Sciences Innovation ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Travere Therapeutics Inc | 7.67% |
| Cogent Biosciences Inc | 7.53% |
| LivaNova PLC | 7.11% |
| Spyre Therapeutics Inc | 6.41% |
| Guardant Health Inc | 5.52% |
| Mirum Pharmaceuticals Inc | 4.92% |
| Corcept Therapeutics Inc | 4.79% |
| United Therapeutics Corp | 4.16% |
| VeraDermics Inc | 3.42% |
| Savara Inc | 3.22% |
LFSC Portfolio Allocation
Asset-class allocation of F/m Emerald Life Sciences Innovation ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.0% |
LFSC Performance
Total returns for LFSC (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 7.6% |
| 1 year | 72.1% |
LFSC Risk Information
Risk metrics for LFSC, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 23.7%
LFSC Costs and Fees
LFSC costs about $54 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.54%
- Gross expense ratio: 0.79%
- Portfolio turnover: 19%
LFSC Cashflows
Over the 12 months to 2026-02, F/m Emerald Life Sciences Innovation ETF had net inflows of $15.43M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | $4.35M |
| 2026-01 | −$991.09K |
| 2025-12 | $3.12M |
| 2025-11 | $3.10M |
| 2025-10 | $937.73K |
| 2025-09 | $574.90K |
LFSC Debt Constituents
No individual debt constituents are reported in F/m Emerald Life Sciences Innovation ETF's latest SEC N-PORT filing.
LFSC Prospectus and SEC Filings
Official F/m Emerald Life Sciences Innovation ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.